Mode
Text Size
Log in / Sign up
Phase 2 Completed N=15 Randomized Triple-blind Treatment

Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population

Migraine Disorders · Headache, Migraine · Pediatrics
Source: ClinicalTrials.gov NCT03055767 ↗
Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Oct 2023
Primary outcomePrimary: Frequency of Migraines — 28; 20; 28 days — p=0.038

Summary

The purpose of the research is to examine the outcomes of pediatric patients receiving Botulinum toxin type A (Botox ®) for the treatment of migraine. There is limited literature on the effectiveness of Botox ® in the treatment of chronic neurological pain in pediatric patients, specifically in the treatment of migraines.

Outcome Measures

OutcomeResultp-value
PRIMARY
Frequency of Migraines
28; 20; 28 0.038 sig
PRIMARY
Intensity of Migraines
8; 5; 7 0.047 sig
PRIMARY
Migraine Duration, in Hours
24; 10; 24 0.148
PRIMARY
Pediatric Migraine Disability Score (PedMIDAS)
4; 3; 4 0.047 sig
SECONDARY
Functionality Improvement
1; 0 0.002 sig
SECONDARY
Difficulty Sleeping
12; 5; 11 0.82
SECONDARY
Hospital Admissions
8; 0; 2 0.006 sig
SECONDARY
Emergency Department (ED) Visits
8; 2; 3 0.039 sig
SECONDARY
Home School
2; 2; 2 0.016 sig
SECONDARY
School Plan Enrollment
11; 10; 10 0.18
SECONDARY
Duration of Benefit
4; 0 <0.001 sig
SECONDARY
Concomitant Headache Medications
3; 1; 2 0.64

Eligibility Criteria

Inclusion Criteria

  • Children aged 8 - 17 years of age with a history of migraine meeting the criteria established in ICHD-II (2004), Section 1. Patients will provide at least 28-day baseline data in the form in the daily diary and must have at least 15 days of reported headache during this period, with at least 4 distinct episodes lasting at least 4 hours each.

Exclusion Criteria

  • Previous use of botulinum toxin of any serotype for any reason
  • Pregnancy.
  • Diagnosis of Myasthenia gravis, Eaton Lambert Syndrome, Amyotrophic Lateral Sclerosis
  • Treatment of headache using acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints, or injection of anesthetics/steroids within 4 weeks prior to the week of screening visit
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03055767). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search